A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
CEL SCI CORP
CVM
$10M
Mkt Cap
$1.18
-0.84%
CEL SCI CORP (CVM) has a 5-year average return on invested capital (ROIC) of -100.9%. This is below average and may indicate limited pricing power.
CEL SCI CORP (CVM) has a market capitalization of $10M. It is classified as a small-cap stock.
CEL SCI CORP (CVM) does not currently pay a regular dividend.
CEL SCI CORP (CVM) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
CEL SCI CORP (CVM) generated $-17 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CEL SCI CORP (CVM) has a debt-to-equity ratio of 0.50. This indicates a conservatively financed balance sheet.
CEL SCI CORP (CVM) reported earnings per share (EPS) of $-3.02 in its most recent fiscal year.
CEL SCI CORP operates in the Biological Products, (No Diagnostic Substances) industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | -567K | - | - | - | - | - |
| Net Income | -24M | -25M | -28M | -38M | -37M | -30M |
| EPS | $-2.55 | $-3.02 | $-199.03 | $-11.31 | $-11.70 | $-10.66 |
| Free Cash Flow | -17M | -17M | -19M | -19M | -28M | -18M |
| ROIC | -149.9% | -119.7% | -125.4% | -66.2% | -72.5% | -120.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.67 | 0.50 | 0.77 | 0.41 | 0.23 | 0.60 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -23M | -25M | -26M | -36M | -36M | -29M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -213.7% | -176.3% | -211.5% | -84.8% | -96.3% | -243.6% |
| Shares Outstanding | 8M | 8M | 0M | 3M | 3M | 3M |
| Metric | 2017 | 2018 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -567K |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 13M | 15M | 19M | 17M | 16M | 11M | 13M | 18M | 23M | 25M | 18M | 16M | 15M |
| SG&A | 7.0M | 11M | 14M | 6.5M | 5.8M | 6.3M | 8.0M | 12M | 13M | 11M | 8.2M | 8.9M | 8.2M |
| EBIT | -20M | -26M | -32M | -24M | -21M | -17M | -20M | -29M | -36M | -36M | -26M | -25M | -23M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -9.2M | -28M | -35M | -12M | -14M | -32M | -22M | -30M | -37M | -38M | -28M | -25M | -24M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 27K | 1K | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 18K | 18K |
| Returns on Capital | |||||||||||||
| ROIC | N/M | -188.0% | -89.6% | -95.0% | N/A | N/A | -156.5% | -120.8% | -72.5% | -66.2% | -125.4% | -119.7% | -149.9% |
| ROE | -134.5% | -325.7% | N/A | 423.1% | N/A | N/A | -431.2% | -243.6% | -96.3% | -84.8% | -211.5% | -176.3% | -213.7% |
| ROA | -68.6% | -189.4% | -145.2% | -43.1% | N/A | N/A | -77.4% | -88.8% | -63.1% | -59.5% | -95.9% | -92.2% | -104.0% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -14M | -23M | -24M | -23M | -14M | -13M | -16M | -15M | -19M | -18M | -19M | -17M | -17M |
| Free Cash Flow | -14M | -23M | -24M | -23M | -14M | -13M | -16M | -18M | -28M | -19M | -19M | -17M | -17M |
| Owner Earnings | -16M | -28M | -30M | -26M | -16M | -17M | -21M | -26M | -33M | -32M | -25M | -21M | -21M |
| CapEx | 102K | 104K | 73K | 31K | 11K | 1K | 178K | 2.7M | 9.0M | 638K | 95K | 38K | 5K |
| Maint. CapEx | 276K | 703K | 680K | 626K | 593K | 575K | 588K | 389K | 447K | 2.0M | 2.1M | 2.1M | 2.0M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.3M | 8.6M | 0 | 0 | 0 | 0 |
| D&A | 276K | 703K | 680K | 626K | 593K | 575K | 588K | 389K | 447K | 2.0M | 2.1M | 2.1M | 2.0M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.6M | 4.0M | 5.1M | 2.1M | 1.4M | 2.7M | 4.4M | 10M | 14M | 11M | 4.3M | 1.9M | 1.6M |
| Debt Repayment | 7K | 8K | 8K | 8K | 4K | 6K | 5K | 800K | 1.1M | 1.4M | 1.8M | 2.0M | 2.0M |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | 5.1M | -3.8M | -29M | -9.4M | 5.2M | -3.0M | 1.1M |
| Cash & Equiv. | 42K | 8.5M | 5.7M | 2.9M | 2.4M | 10M | 8.4M | 16M | 36M | 23M | 4.7M | 11M | 6.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | 14M | 12M | 13M | 12M | 8.0M | 5.7M | 5.1M |
| Debt/Equity | 0.62 | 0.81 | -7.00 | -37.64 | N/A | N/A | 2.63 | 0.60 | 0.23 | 0.41 | 0.77 | 0.50 | 0.67 |
| Interest Coverage | -116.6 | -156.7 | -249.2 | -12.6 | -11.3 | -9.6 | -11.2 | -24.2 | -31.5 | -33.4 | -35.3 | -38.2 | -38.2 |
| Equity | 6.7M | 11M | -4.8M | -679K | N/A | N/A | 5.1M | 20M | 57M | 32M | 13M | 16M | 11M |
| Total Assets | 11M | 19M | 29M | 25M | N/A | N/A | 28M | 41M | 76M | 51M | 27M | 28M | 23M |
| Total Liabilities | 4.1M | 8.8M | 33M | 26M | 26M | 30M | 22M | 21M | 19M | 18M | 14M | 12M | 12M |
| Intangibles | 318K | 324K | 292K | 257K | 223K | 258K | 312K | N/A | 276K | 212K | 165K | 120K | 102K |
| Retained Earnings | -212M | -239M | -274M | -285M | -300M | -332M | -354M | -382M | -418M | -455M | -514M | -539M | -545M |
| Working Capital | -1.0M | 8.5M | 1.6M | 1.4M | -6.6M | 2.2M | 6.8M | 13M | 41M | 21M | 1.4M | 6.5M | 2.0M |
| Current Assets | 2.5M | 12M | 8.3M | 5.5M | 4.2M | 11M | 9.8M | 18M | 45M | 25M | 6.1M | 12M | 7.0M |
| Current Liabilities | 3.5M | 3.2M | 6.7M | 4.0M | 11M | 9.2M | 3.0M | 4.3M | 3.9M | 4.7M | 4.6M | 5.1M | 5.0M |
| Per Share Data | |||||||||||||
| EPS | -274.95 | -76.98 | -65.93 | -585.39 | -1,432.50 | -1,402.50 | -9.23 | -10.66 | -11.70 | -11.31 | -199.03 | -3.02 | -2.55 |
| Owner EPS | -490.35 | -74.60 | -56.29 | -1,313.00 | -1,565.39 | -735.69 | -8.90 | -9.08 | -10.49 | -9.50 | -181.97 | -2.51 | -2.45 |
| Book Value | 199.58 | 29.16 | -9.05 | -34.54 | N/A | N/A | 2.14 | 6.95 | 18.02 | 9.67 | 92.86 | 1.90 | 1.32 |
| Cash Flow/Share | -403.58 | -62.00 | -45.29 | -1,173.70 | -1,369.43 | -589.57 | -6.81 | -5.38 | -5.99 | -5.48 | -135.75 | -2.04 | -2.59 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.0M | 0.4M | 0.5M | 0.0M | 0.0M | 0.0M | 2.4M | 2.8M | 3.1M | 3.3M | 0.1M | 8.4M | 8.4M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | 54.7 | 22.5 | 8.2 | 4.7 | 21.4 | 4.7 | 0.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -15.7% | -28.0% | -19.8% | -70.5% | -2819.9% | -485.3% | -5.9% | -4.0% | -6.0% | -12.4% | -6.9% | -22.8% | -171.2% |
| Market Cap | 87M | 82M | 121M | 33M | 489K | 2.8M | 281M | 443M | 462M | 153M | 275M | 75M | 9.9M |
| Avg. Price | 1,980.30 | 797.20 | 558.81 | 376.54 | 91.74 | 60.37 | 150.20 | 351.19 | 461.15 | 174.07 | 52.51 | 11.81 | 1.18 |
| Year-End Price | 1,312.50 | 675.00 | 480.00 | 202.50 | 48.60 | 121.50 | 270.00 | 360.00 | 339.90 | 105.90 | 32.70 | 8.95 | 1.18 |
CEL SCI CORP passes 0 of 9 quality checks, indicating weak fundamentals.
CEL SCI CORP (CVM) has a return on equity (ROE) of -176.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for CEL SCI CORP (CVM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CEL SCI CORP (CVM) has a book value per share of $1.90, based on its most recent annual SEC filing.
No recent press releases.